Searchable abstracts of presentations at key conferences in endocrinology

ea0081ep964 | Thyroid | ECE2022

Therapeutic approach to the diagnosis of Bethesda 5

Barrera-Martin Ana , Rosa Alhambra Exposito Mª , Moreno-Moreno Paloma , Angeles Galvez Moreno Maria

Introduction: Thyroid nodules are very common in the general population (20-75% ultrasound). There are clinical management criteria established by international societies and standardized cytological diagnostic criteria (Bethesda). However, there is still uncertainty in the management of category 5.Objectives: To evaluate the clinical attitude to the cytological diagnosis of Bethesda category 5 (B5) in thyroid fine-needle aspiration cytology (FNA). And s...

ea0063gp93 | Thyroid Nodules and Cancer | ECE2019

Tirads classification and final diagnosis of thyroid nodules classified as bethesda-3 after fine-needle aspiration

Rosa Alhambra Exposito Maria , Barrera Martin Ana , Segui Azpilcueta Pedro , Angeles Galvez Moreno Maria

Introduction: Ultrasound is the main diagnostic tool for imaging pathology of the thyroid gland. The TI-RADS classification allows the evaluation of a risk of malignancy in the case of thyroid nodules, indicating the need to perform a puncture for a histological study. Bethesda system classifies them according to the cytological malignancy risk. Bethesda category 3 (B3) comprises ‘follicular lesion of undetermined significance’ or ‘atypia of undetermined signifi...

ea0063p282 | Pituitary and Neuroendocrinology 1 | ECE2019

Cushing disease: Clinical presentation

Moreno-Moreno Paloma , Munoz-Jimenez Concepcion , Barrera-Martin Ana , Galvez-Moreno Maria Angeles

Objective: Cushing’s disease (CD) accounts for approximately 80% of cases of Cushing’s syndrome. Its clinic is nonspecific and its diagnosis difficult. The objective of this study is to review the most frequent clinical signs of this disease in our environment and compare it with that described in the literature.Patients and methods: Retrospective descriptive study of patients with CD. We included all patients diagnosed with CD (2005–2017)...

ea0063p287 | Pituitary and Neuroendocrinology 1 | ECE2019

Diagnostic tests in Cushing’s disease

Moreno-Moreno Paloma , Alcantara-Laguna Maria Dolores , Leon-Idougourram Soraya , Galvez-Moreno Maria Angeles

Objective: Cushing’s disease (CD) accounts for approximately 80% of cases of Cushing’s syndrome. Diagnosis of CD is difficult, it is carried out with a screening test and confirmation test. The aim of this study is to describe the diagnostic results of the different diagnostic tests used in the diagnosis of CD in our environment.Patients and methods: Retrospective descriptive study of patients with CD. We included all patients diagnosed with CD...

ea0049ep1159 | Male Reproduction | ECE2017

Induction of male puberty in patients with hypogonadism hypogonadotrope with subcutaneous gonadotropin

Moreno-Moreno Paloma , Munoz-Jimenez Concepcion , Alhambra-Exposito Maria Rosa , Galvez-Moreno Maria Angeles

Objective: The most used therapeutic guidelines for the induction of male puberty in hypogonadotropic hypogonadism (HH) are GnRH in subcutaneous pulsatile infusion and HCG in monotherapy or combined with FSH in intramuscular injection. The objective of this study was to evaluate the efficacy of subcutaneous HCG with or without FSH in induction of male puberty in patients with HH.Patients and methods: Descriptive study of patients with HH treated with HCG...

ea0041ep753 | Neuroendocrinology | ECE2016

Prognostic factors of pituitary growth hormone-secreting tumors

Alhambra Exposito Maria Rosa , Ibanez Costa Alejandro , Moreno Paloma Moreno , Galvez Moreno Maria Angeles

Background: Acromegaly is the consequence of excessive growth hormone (GH) secretion, usually produced by a pituitary adenoma. Transphenoidal surgery is the first-choice treatment; however, the development of new drug therapies in the last years, specially the somatostatin analogues (SSA), has open new and promising avenues for the treatment of pituitary tumors.Objective: To determine whether a detailed knowledge of the clinico-pathological and radiologi...

ea0037ep441 | Diabetes (complications & therapy) | ECE2015

Glargine insulin treatment during pregnancy in type 1 diabetes mellitus

Moreno-Moreno Paloma , Palomares-Ortega Rafael , Munoz-Jimemez Concepcion , Galvez-Moreno Maria Angeles

Objective: The aim of this study was to evaluate maternal and neonatal outcomes in women with type 1 diabetes mellitus (DM1), and analysing differences associated to insulin glargine exposure during pregnancy.Patients and methods: Retrospective descriptive study of pregnancies in women with DM1 (2004–2012). Variables analysed: baseline characteristics (age, time of diabetes evolution, microvascular complications, and weight), maternal outcomes (weig...

ea0037ep476 | Diabetes (complications & therapy) | ECE2015

Pregnancy planning in type 1 diabetes mellitus

Moreno-Moreno Paloma , Palomares-Ortega Rafael , Barrera-Martin Ana , Galvez-Moreno Maria Angeles

Objective: The aim of this study was to determine the prevalence of pregnancy planning in women with type 1 diabetes mellitus (DM1) and analysing differences associated with unplanned pregnancy.Patients and methods: Retrospective descriptive study of pregnancies in women with DM1 (2004–2012). Variables analysed: age, time of diabetes evolution, microvascular complications, and maternal outcomes (HbA1c, preeclampsia, abortions, and Caesarean section)...

ea0056p439 | Diabetes complications | ECE2018

Hyperlipidemia during gestational diabetes: maternal and offspring complications

Herrera-Martinez Aura D. , Palomares Ortega Rafael , Bahamondes Opazo Rodrigo , Moreno Moreno Paloma , Galvez Moreno Maria A.

Lipid profile suffers adaptive changes during pregnancy due to estrogen stimulation and insulin resistance. Several relations have been suggested between maternal lipid profile, glucose tolerance, endothelial cell dysfunction and long-term cardiovascular risk; the effects of maternal lipid profile metabolism in fetal growth are also inconclusive. Since a regular evaluation and follow-up of lipid profile during pregnancy has not been stablished yet, we aimed to evaluate the inc...

ea0056p484 | Diabetes therapy | ECE2018

Dapagliflozin after liraglutide in patients with type 2 diabetes

Moreno-Moreno Paloma , Munoz-Jimenez Concepcion , Alhambra-Exposito Maria Rosa , Galvez-Moreno Maria Angeles

Objective: To evaluate the efficacy of dapagliflozin for glycemic control and progression of weight loss after stabilization with liraglutide 1.8 mg.Patients and methods: Descriptive study: patients with tipo 2 diabetes (DM-2) in treatment with metformin and liraglutide 1.8 mg, optimal metabolic control, which after stabilization in weight loss, liraglutide is suspended and dapagliflozin is added. Variables analyzed baseline and at 6 months after treatme...